CYPSEDO (Cipepofol): FDA Approval, Mechanism of Action, Dosage, Adverse Effects and Clinical Pharmacy Perspective
1. What is CYPSEDO (Cipepofol) and FDA Regulatory Status?
CYPSEDO is the proprietary brand name for Cipepofol (HSK3486), synthesized by Haisco Pharmaceutical Group as a next-generation structural analog of propofol.
NMPA Approval (China): Approved for procedural sedation during endoscopy, fiberoptic bronchoscopy, induction and maintenance of general anesthesia, and ICU sedation. US FDA Status: Investigational New Drug (IND) cleared by the US FDA for multi-center Phase 3 clinical trials in the United States.
2. Molecular Mechanism of Action & GABAA Receptor Dynamics
Cipepofol functions as a potent positive allosteric modulator of GABAA receptors in the central nervous system, binding specifically to transmembrane beta-subunits and increasing chloride ion influx to hyperpolarize neuronal membranes.
Hyperpolarization shuts down neuronal excitability across the reticular activating system and cerebral cortex, rapidly producing sedation and amnesia.
3. Cipepofol vs. Propofol: Comprehensive Clinical Comparison
Because cipepofol is 5x more potent, 80% less drug mass is dissolved in the lipid emulsion, dropping free aqueous drug below the nociceptor pain threshold (<5% pain vs >60% with propofol).
Clinical trials demonstrate significantly greater mean arterial pressure stability and rapid recovery of orientation (Aldrete score >= 9 in 5.8 to 7.4 minutes).
4. Dosing Guidelines, Procedural Sedation & Anesthesia Induction
Procedural Sedation: 0.4 mg/kg IV bolus over 30–60 seconds (0.3 mg/kg in elderly); supplemental top-up 0.1–0.2 mg/kg IV as needed.
General Anesthesia Induction: 0.4–0.5 mg/kg IV bolus over 30 seconds.
Anesthesia Maintenance: 0.4–1.5 mg/kg/hour continuous IV infusion.
ICU Sedation: 0.1–0.4 mg/kg/hour continuous infusion.
From a clinical pharmacy perspective, the explicit dosage reduction mandated for patients with a body mass index exceeding 40 kg/m² underscores the critical need for precise anthropometric assessment before anesthesia induction. Visual weight estimation frequently misclassifies patients near the class III obesity threshold, introducing a significant risk of inadvertent oversedation, prolonged recovery, or exacerbated respiratory depression. Healthcare professionals can utilize a verified BMI calculator during preoperative medication reconciliation to accurately determine body mass index, distinguish normal from elevated adiposity tiers, and calculate the appropriate individualized cipepofol dose (0.2–0.25 mg/kg IV) rather than defaulting to standard adult regimens.
5. Adverse Effect Profile, Contraindications & Safety Precautions
Adverse effects include dose-dependent respiratory depression, transient hypoxemia, hypotension, and bradycardia. Mandatory monitoring includes SpO2, EtCO2, continuous ECG, and non-invasive blood pressure.
Contraindicated in patients with severe allergies to egg, soy, or lipid emulsions, or in uncorrected circulatory shock.
6. Clinical Pharmacy Perspective, Oncology Roles & Medication Safety
Interventional Oncology: Widely beneficial during percutaneous tumor biopsies, liver tumor radiofrequency ablation, chemoembolization, and endoscopic ultrasound in fragile cancer patients.
Pharmacy Best Practices: Independent double-check, smart infusion pump hard limits, and strict 6-hour discard rule for preservative-free lipid emulsion.
Key Clinical Takeaways
- CYPSEDO (Cipepofol / HSK3486) is a stereoselective GABAA modulator with 4 to 5 times greater potency than propofol.
- Approved by China NMPA; actively undergoing US FDA Phase 3 clinical evaluation under IND.
- Standard adult procedural sedation bolus is 0.4 mg/kg IV (0.3 mg/kg in elderly).
- Drastically reduces vascular injection pain (<5% vs >60% with propofol) due to lower free aqueous drug mass.
- Superior hemodynamic stability is especially valuable for interventional oncology and fragile patients.
Frequently Asked Questions
Is CYPSEDO (Cipepofol) approved by the US FDA?
It is cleared as an Investigational New Drug (IND) by the US FDA for Phase 3 trials in procedural sedation and anesthesia induction, while fully approved by China NMPA.
Why does Cipepofol avoid propofol injection pain?
Due to its 5x higher potency, 80% less drug is in the lipid emulsion, keeping free aqueous concentration below the vascular nociceptor pain threshold.
Can Cipepofol be dosed like Propofol?
NO. Cipepofol is 5 times more potent (0.4 mg/kg vs 2.0 mg/kg). Dosing like propofol causes a fatal 500% overdose.